Opko Health (NASDAQ:OPK)‘s stock had its “buy” rating restated by research analysts at Barrington Research in a research report issued to clients and investors on Friday, AnalystRatings.com reports.
Other research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. BidaskClub raised shares of Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 23rd. Finally, Piper Sandler increased their target price on shares of Opko Health from $4.00 to $6.00 in a research report on Wednesday, July 8th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $4.63.
OPK stock traded down $0.76 during trading on Friday, reaching $5.15. The stock had a trading volume of 35,762,149 shares, compared to its average volume of 23,464,950. Opko Health has a one year low of $1.12 and a one year high of $6.47. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $3.78 and its two-hundred day moving average is $2.31. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -15.61 and a beta of 2.29.
In other news, CEO Phillip Md Et Al Frost bought 250,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were acquired at an average cost of $2.20 per share, for a total transaction of $550,000.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $6,751,692.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders purchased 850,000 shares of company stock valued at $1,795,000. 40.90% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC bought a new stake in Opko Health in the 1st quarter worth $30,000. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its holdings in Opko Health by 108.3% in the 1st quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 25,000 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 13,000 shares during the last quarter. Great West Life Assurance Co. Can bought a new stake in Opko Health in the 4th quarter worth $35,000. United Capital Financial Advisers LLC grew its holdings in Opko Health by 27.3% in the 1st quarter. United Capital Financial Advisers LLC now owns 26,101 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Kovack Advisors Inc. grew its holdings in Opko Health by 37.8% in the 1st quarter. Kovack Advisors Inc. now owns 29,151 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 23.49% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.